Actual Driving Performance and Psychomotor Function in Healthy Subjects After Acute and Subchronic Treatment With Escitalopram, Mirtazapine, and Placebo: A Crossover Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The effects of escitalopram 10 to 20 mg/day and mirtazapine 30 to 45 mg/day on actual driving and psychomotor performance of 18 healthy subjects were determined in a randomized, double-blind, placebo-controlled, multiple-dose, 3-way crossover trial. METHOD: Each treatment period lasted for 15 days and was separated from the next period by a washout period of at least 13 days. Subjects received an evening dose of escitalopram 10 mg, mirtazapine 30 mg, or placebo from days 1 to 7 and an evening dose of escitalopram 20 mg, mirtazapine 45 mg, or placebo from days 8 to 15. On days 2, 9, and 16, reflecting acute period, dose increase, and steady state, respectively, the Road Tracking Test was performed. The main parameter was standard deviation of lateral position. Psychomotor performance was also assessed on days 2, 9, and 16 by laboratory computer tasks. Subjective sleep quality was measured with the Groninger Sleep Quality Scale, and mood was measured by visual analogue scales. RESULTS: Treatment differences were apparent during the acute treatment period, in which subjects treated with mirtazapine 30 mg performed less well on the driving test as compared to placebo. The Divided Attention Task results also revealed a significant increase in tracking error after a single dose of mirtazapine 30 mg as compared to placebo. Mirtazapine decreased feelings of alertness and contentedness. Mirtazapine did not affect performance on days 9 and 16 of treatment. Escitalopram did not affect driving, psychomotor performance, or subjective mood throughout treatment. CONCLUSION: Driving performance, as well as psychomotor functioning, was not affected by escitalopram treatment in healthy subjects. Driving performance was significantly impaired after ingestion of mirtazapine 30 mg during the acute treatment period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dassanayake, T., Michie, P., Carter, G., & Jones, A. (2011) · Drug Safety · doi:10.2165/11539050-000000000-00000 · Cited by 253
Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders
Croom, K. F., Perry, C. M., & Plosker, G. L. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00006 · Cited by 158
Primum Non Nocere: An Evolutionary Analysis of Whether Antidepressants Do More Harm than Good
Andrews, P. W., Thomson, J. A., Amstadter, A., & Neale, M. C. (2012) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00117 · Cited by 120
A Review of Modern Antidepressants Effects on Neurocognitive Function
Biringer, E., Rongve, A., & Lund, A. (2009) · Current Psychiatry Reviews · doi:10.2174/157340009788971137 · Cited by 73
Neurocognitive profile analysis in obsessive-compulsive disorder
BURDICK, K. E., ROBINSON, D. G., MALHOTRA, A. K., & SZESZKO, P. R. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708080727 · Cited by 50
Metadata
- Authors
- Wingen, M., Bothmer, J., Langer, S., & Ramaekers, J. G.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-04-15
- Volume
- 66
- Issue
- 04
- Pages
- 436-443
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1979078007
- Cited by
- 94
- References
- 0
- FWCI
- 32.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Actual Driving Performance and Psychomotor Function in Healthy Subjects After Acute and Subchronic Treatment With Escitalopram, Mirtazapine, and Placebo: A Crossover Trial. https://app.cochat.ai/papers/10.4088/jcp.v66n0405
- The paper
- Wingen, M., Bothmer, J., Langer, S., & Ramaekers, J. G. (2005). Actual Driving Performance and Psychomotor Function in Healthy Subjects After Acute and Subchronic Treatment With Escitalopram, Mirtazapine, and Placebo: A Crossover Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n0405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.